SMT201600099B - Derivati citotossici di benzodiazepine - Google Patents

Derivati citotossici di benzodiazepine

Info

Publication number
SMT201600099B
SMT201600099B SM201600099T SM201600099T SMT201600099B SM T201600099 B SMT201600099 B SM T201600099B SM 201600099 T SM201600099 T SM 201600099T SM 201600099 T SM201600099 T SM 201600099T SM T201600099 B SMT201600099 B SM T201600099B
Authority
SM
San Marino
Prior art keywords
benzodiazepine
cytotoxic derivatives
cytotoxic
derivatives
Prior art date
Application number
SM201600099T
Other languages
English (en)
Inventor
Wei Li
Michael Miller
Nathan Fishkin
Ravi V J Chari
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600099(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SMT201600099B publication Critical patent/SMT201600099B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201600099T 2011-02-15 2016-04-08 Derivati citotossici di benzodiazepine SMT201600099B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161443062P 2011-02-15 2011-02-15
US201161443092P 2011-02-15 2011-02-15
US201161483499P 2011-05-06 2011-05-06
PCT/US2012/025252 WO2012128868A1 (en) 2011-02-15 2012-02-15 Cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
SMT201600099B true SMT201600099B (it) 2016-04-29

Family

ID=45755579

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20190181T SMT201900181T1 (it) 2011-02-15 2012-02-15 Metodi di preparazione di coniugati
SM201600099T SMT201600099B (it) 2011-02-15 2016-04-08 Derivati citotossici di benzodiazepine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20190181T SMT201900181T1 (it) 2011-02-15 2012-02-15 Metodi di preparazione di coniugati

Country Status (29)

Country Link
US (12) US9353127B2 (it)
EP (6) EP2675479B1 (it)
JP (8) JP5826863B2 (it)
KR (6) KR20200141534A (it)
CN (5) CN107050468A (it)
AU (5) AU2012231640B2 (it)
BR (2) BR112013020540B1 (it)
CA (4) CA3034596C (it)
CY (2) CY1117340T1 (it)
DK (2) DK2675480T3 (it)
ES (2) ES2567418T3 (it)
HR (2) HRP20190576T1 (it)
HU (2) HUE028736T2 (it)
IL (6) IL279304B (it)
LT (1) LT2675480T (it)
ME (1) ME02381B (it)
MX (3) MX343337B (it)
MY (2) MY183977A (it)
PL (2) PL2675479T3 (it)
PT (1) PT2675480T (it)
RS (2) RS54667B1 (it)
RU (4) RU2748733C2 (it)
SG (4) SG10202007640VA (it)
SI (2) SI2675480T1 (it)
SM (2) SMT201900181T1 (it)
TW (1) TWI617555B (it)
UA (1) UA120696C2 (it)
WO (3) WO2012112687A1 (it)
ZA (2) ZA201305386B (it)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
EP2675479B1 (en) 2011-02-15 2016-01-13 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SMT201900114T1 (it) * 2011-03-29 2019-02-28 Immunogen Inc Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
MX341524B (es) 2011-09-20 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
EP2751110B1 (en) 2011-10-14 2017-04-19 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
CN104220595A (zh) * 2012-04-04 2014-12-17 株式会社英仙蛋白质科学 抗cdh3(p-钙粘着蛋白）抗体的药剂偶联物
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
WO2014031566A1 (en) * 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057122A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2906249B1 (en) 2012-10-12 2018-06-27 MedImmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
SMT201800346T1 (it) * 2012-10-12 2018-09-13 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
ES2713164T3 (es) 2012-10-12 2019-05-20 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2916835A4 (en) * 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
TWI716339B (zh) 2012-12-21 2021-01-21 荷蘭商台醫（有限合夥）公司 親水性自消耗連接子及彼等之共軛物
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
CN110627797A (zh) * 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
KR102274714B1 (ko) * 2013-03-13 2021-07-09 씨젠 인크. 사이클로덱스트린 및 항체-약물 포합체 제형
DK2968494T3 (en) 2013-03-13 2019-03-04 Seattle Genetics Inc ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3038634A4 (en) 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
CN105873612A (zh) * 2013-08-28 2016-08-17 施特姆森特克斯股份有限公司 改造的抗-dll3缀合物以及应用方法
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
CN115124573A (zh) 2013-09-02 2022-09-30 杭州多禧生物科技有限公司 应用于细胞结合分子-药物共轭体的新型细胞毒性分子
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
NZ758050A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
HK1231400A1 (zh) 2014-02-11 2017-12-22 Seattle Genetics, Inc. 蛋白质的选择性还原
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
EP3145542A4 (en) * 2014-05-20 2018-01-17 ImmunoGen, Inc. Methods for characterizing and treating acute myeloid leukemia
AU2015276821A1 (en) 2014-06-20 2017-01-12 Abgenomics International Inc. Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US20160058884A1 (en) * 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
TW201609152A (zh) * 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
TW202417447A (zh) 2014-09-03 2024-05-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
GB201416112D0 (en) * 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
KR20170055521A (ko) * 2014-09-17 2017-05-19 제넨테크, 인크. 항-her2 항체를 포함하는 면역콘주게이트
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016094505A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
AU2015360282B2 (en) 2014-12-11 2021-04-01 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
PE20171185A1 (es) 2015-01-14 2017-08-22 Bristol Myers Squibb Co Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
US9527871B2 (en) 2015-01-14 2016-12-27 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
EP3268046A4 (en) * 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases
JP6773677B2 (ja) 2015-03-17 2020-10-21 アローヘッド ファーマシューティカルズ インコーポレイテッド 改善されたジスルフィド含有アルキン連結剤
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EA039619B1 (ru) * 2015-05-20 2022-02-17 Иммуноджен, Инк. Способ получения индолинобензодиазепиновых соединений
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
CA2990030A1 (en) 2015-06-23 2016-12-29 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
LT3313884T (lt) 2015-06-29 2021-03-10 Immunogen, Inc. Anti-cd123 antikūnai, konjugatai ir jų dariniai
PL3313845T3 (pl) * 2015-06-29 2021-01-11 Immunogen, Inc. Koniugaty przeciwciał modyfikowanych cysteiną
EP3653628B1 (en) * 2015-07-21 2022-09-14 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
FI3380525T3 (fi) * 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
CN108883196A (zh) * 2016-02-05 2018-11-23 米伦纽姆医药公司 靶向gcc的抗体－药物缀合物
EP3411077A1 (en) * 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
PH12018501777B1 (en) * 2016-04-20 2022-08-10 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017184942A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
TW201808936A (zh) 2016-05-18 2018-03-16 美商梅爾莎納醫療公司 吡咯并苯并二氮呯類及其共軛物
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
SG11201900699QA (en) 2016-08-09 2019-02-27 Seattle Genetics Inc Drug conjugates with self-stabilizing linkers having improved physiochemical properties
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MA46779A (fr) * 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
CA3042679A1 (en) * 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
WO2018098258A2 (en) * 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
CN110267685B (zh) 2016-12-23 2023-06-20 伊缪诺金公司 靶向adam9的免疫缀合物及其使用方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7246321B2 (ja) 2017-01-24 2023-03-27 インネイト ファーマ ＮＫｐ４６結合物質
IL287405B (en) * 2017-01-25 2022-07-01 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
CN106841192B (zh) * 2017-04-18 2019-05-03 乐凯（沈阳）科技产业有限责任公司 一种二氮杂卓结构指示剂检测甲醛方法及其应用
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
IL305224B2 (en) 2017-04-20 2024-09-01 Immunogen Inc Methods of preparing indolinobenzodiazepine derivatives
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
WO2019018892A1 (en) 2017-07-26 2019-01-31 The University Of Queensland COMPOUNDS CONTAINING DISULFIDE BOND AND USES THEREOF
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2018342527B2 (en) 2017-09-29 2024-06-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
US11274121B2 (en) * 2018-01-12 2022-03-15 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019189453A1 (en) 2018-03-28 2019-10-03 Mitsubishi Tanabe Pharma Corporation DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020102051A1 (en) 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
MA54225A (fr) 2018-11-12 2021-09-22 Immunogen Inc Procédés de préparation de dérivés de benzodiazépine cytotoxiques
CN111393502B (zh) * 2019-01-03 2022-04-29 北京京东方技术开发有限公司 一种类肽及其制备方法和用途
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JOP20210211A1 (ar) 2019-02-08 2023-01-30 Janssen Pharmaceuticals Inc طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
CN113661172A (zh) * 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
CN113766954B (zh) 2019-04-26 2024-09-24 伊缪诺金公司 喜树碱衍生物
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN115955980A (zh) 2020-04-10 2023-04-11 思进公司 电荷可变接头
CA3196198A1 (en) 2020-11-25 2022-06-02 Manel KRAIEM Treatment of cancer
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
MX2023010819A (es) 2021-03-18 2023-09-28 Seagen Inc Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
CN117813287A (zh) 2021-08-13 2024-04-02 伊缪诺金公司 用于制备细胞毒性苯二氮卓衍生物的改进方法
JP7707943B2 (ja) * 2022-01-25 2025-07-15 株式会社三洋物産 遊技機
JP7707941B2 (ja) * 2022-01-25 2025-07-15 株式会社三洋物産 遊技機
JP7707940B2 (ja) * 2022-01-25 2025-07-15 株式会社三洋物産 遊技機
JP7707942B2 (ja) * 2022-01-25 2025-07-15 株式会社三洋物産 遊技機
CA3245954A1 (en) 2022-05-25 2023-11-30 Innate Pharma NECTIN-4 LIAISON OFFICERS
EP4548932A1 (en) 2022-06-30 2025-05-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
IL318313A (en) 2022-07-12 2025-03-01 Cytomx Therapeutics Inc EPCAM antibody conjugates and their uses
TW202409080A (zh) * 2022-07-26 2024-03-01 美商沙塔克實驗室股份有限公司 用於治療卵巢癌之組合療法
WO2024076973A1 (en) * 2022-10-04 2024-04-11 Brown University Compositions and methods of delivering large proteins
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
US3453266A (en) 1966-03-14 1969-07-01 American Home Prod 1,2,5-benzothiadiazepine 1,1-dioxides
US3506646A (en) 1966-06-27 1970-04-14 American Home Prod Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US3875162A (en) 1973-07-26 1975-04-01 Squibb & Sons Inc Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds
US4003905A (en) 1974-12-11 1977-01-18 E. R. Squibb & Sons, Inc. Diels-alder adducts of benzdiazepines
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS57131791A (en) 1980-12-31 1982-08-14 Fujisawa Pharmaceut Co Ltd Benzodiazepine derivative and its preparation
US4444688A (en) 1981-05-11 1984-04-24 Ciba-Geigy Corporation Imidazobenzothiadiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
JP2920385B2 (ja) 1988-08-18 1999-07-19 武田薬品工業株式会社 １，２，５‐ベンゾチアジアゼピン誘導体，その製造法および用途
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
ATE248812T1 (de) 1997-02-03 2003-09-15 Pfizer Prod Inc Arylsulfonylhydroxamsäurederivate
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
TR199901926T2 (xx) 1997-02-11 1999-12-21 Pfizer Inc. Arils�lfonil hidroksamik asit t�revleri
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
PT1003720E (pt) 1997-08-08 2004-07-30 Pfizer Prod Inc Derivados de acido ariloxiarilsulfonilamino hidroxamico
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6156746A (en) 1998-08-25 2000-12-05 Bristol-Myers Squibb Company 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DK1413582T3 (da) 1998-08-27 2006-07-17 Spirogen Ltd Dimere pyrrolobenzodiazepiner
PT1004578E (pt) 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
FR2800507B1 (fr) 1999-10-27 2002-01-04 Valeo Systemes Dessuyage Commutateur electrique rotatif, notamment pour un moteur d'essuie-glace de vehicule automobile
JP3287409B2 (ja) 1999-10-28 2002-06-04 日本精工株式会社 ロック機構付シートベルト用リトラクターを備えたシートベルト装置
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP2003534384A (ja) * 2000-05-26 2003-11-18 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性ペプチド
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20040242545A1 (en) 2001-07-26 2004-12-02 Santen Phamaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
MXPA04004064A (es) 2001-10-30 2004-09-06 Pharmacia Corp Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AU2003255529B2 (en) 2002-07-10 2008-11-20 Laboratoires Serono Sa Use of compounds for increasing spermatozoa motility
BR0312650A (pt) 2002-07-10 2005-05-03 Applied Research Systems Derivados de benzeno fundido azolidinona-vinila
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
FR2850654A1 (fr) 2003-02-03 2004-08-06 Servier Lab Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2314309C2 (ru) * 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
ATE413407T1 (de) 2003-03-31 2008-11-15 Council Scient Ind Res Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür
RU2338747C2 (ru) * 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
DE602006010386D1 (en) 2005-07-08 2009-12-24 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
US7772485B2 (en) 2005-07-14 2010-08-10 Konarka Technologies, Inc. Polymers with low band gaps and high charge mobility
ITRM20050416A1 (it) 2005-08-03 2007-02-04 Uni Degli Studi Di Roma Tor Vergata Derivati delle benzodiazepine e loro usi in campo medico.
CA2617953C (en) 2005-08-09 2013-12-17 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
ATE427949T1 (de) 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
JP2009526778A (ja) 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
SI2019104T1 (sl) * 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
ATE543826T1 (de) * 2007-08-01 2012-02-15 Council Scient Ind Res Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s
US20100003641A1 (en) 2007-08-15 2010-01-07 Hansen John P Dental crown system
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
MX2010011808A (es) 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
EP3100745B1 (en) * 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
ES2513915T3 (es) * 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
CN102725739A (zh) 2009-05-18 2012-10-10 西山修平 虚拟单一存储装置上的元信息共享型分布式数据库系统
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
NZ602932A (en) * 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
EP2675479B1 (en) * 2011-02-15 2016-01-13 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2014031566A1 (en) * 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP2015202619A (ja) * 2014-04-14 2015-11-16 独立行政法人 国立印刷局 凹版版面

Also Published As

Publication number Publication date
BR112013019913A2 (pt) 2017-10-17
IL227963A (en) 2017-08-31
IL227964A0 (en) 2013-09-30
USRE49918E1 (en) 2024-04-16
JP6216356B2 (ja) 2017-10-18
US20140088089A1 (en) 2014-03-27
US9534000B2 (en) 2017-01-03
US20160108129A1 (en) 2016-04-21
US9840564B2 (en) 2017-12-12
MX2013009417A (es) 2014-08-21
EP2675479A1 (en) 2013-12-25
EP3498303A1 (en) 2019-06-19
IL293365A (en) 2022-07-01
ZA201704808B (en) 2020-11-25
AU2017268554A1 (en) 2017-12-21
AU2017268554B2 (en) 2019-08-15
ES2567418T3 (es) 2016-04-22
JP6703632B2 (ja) 2020-06-03
MX384514B (es) 2025-03-14
US8889669B2 (en) 2014-11-18
NZ613121A (en) 2015-05-29
RU2013142179A (ru) 2015-03-27
SG191955A1 (en) 2013-08-30
SMT201900181T1 (it) 2019-05-10
SG191965A1 (en) 2013-08-30
AU2016200752A1 (en) 2016-02-25
ES2717657T3 (es) 2019-06-24
HUE043976T2 (hu) 2019-09-30
PL2675480T3 (pl) 2019-07-31
EP3053600A1 (en) 2016-08-10
RU2631498C2 (ru) 2017-09-25
CN103687623B (zh) 2017-06-09
US9868791B2 (en) 2018-01-16
RS54667B1 (sr) 2016-08-31
TWI617555B (zh) 2018-03-11
EP3666289A1 (en) 2020-06-17
US9169272B2 (en) 2015-10-27
IL254055A0 (en) 2017-10-31
HUE028736T2 (en) 2017-01-30
JP2016040298A (ja) 2016-03-24
BR112013020540A2 (pt) 2017-03-21
MX343337B (es) 2016-11-01
HRP20190576T1 (hr) 2019-05-17
JP6526138B2 (ja) 2019-06-05
NZ613162A (en) 2015-10-30
PT2675480T (pt) 2019-04-15
RU2748733C2 (ru) 2021-05-31
US20170044266A1 (en) 2017-02-16
RU2017131902A (ru) 2019-02-06
CA3034596C (en) 2021-05-25
CA3110544A1 (en) 2012-09-27
WO2012128868A1 (en) 2012-09-27
US9434748B2 (en) 2016-09-06
ZA201305386B (en) 2015-11-25
PL2675479T3 (pl) 2016-09-30
AU2016200752B2 (en) 2017-08-31
DK2675479T3 (en) 2016-04-11
US9353127B2 (en) 2016-05-31
US10570212B2 (en) 2020-02-25
WO2012112687A1 (en) 2012-08-23
BR112013019913B1 (pt) 2021-01-05
CA2824864A1 (en) 2012-09-27
RU2017117634A3 (it) 2020-08-26
SI2675480T1 (sl) 2019-05-31
US20130302359A1 (en) 2013-11-14
RS58620B1 (sr) 2019-05-31
KR20140010067A (ko) 2014-01-23
AU2012217719B2 (en) 2015-11-05
JP2014521591A (ja) 2014-08-28
AU2012217719A1 (en) 2013-04-18
CA2824864C (en) 2019-04-09
SI2675479T1 (sl) 2016-04-29
RU2017117634A (ru) 2018-11-01
CN107335061A (zh) 2017-11-10
CN103687623A (zh) 2014-03-26
KR20200140939A (ko) 2020-12-16
US10364294B2 (en) 2019-07-30
JP2022009073A (ja) 2022-01-14
DK2675480T3 (en) 2019-04-15
RU2017131902A3 (it) 2020-11-05
MY183977A (en) 2021-03-17
CN103702686A (zh) 2014-04-02
AU2019264595A1 (en) 2019-12-05
JP2024026207A (ja) 2024-02-28
JP2020143102A (ja) 2020-09-10
US8765740B2 (en) 2014-07-01
AU2012231640A1 (en) 2013-05-02
SG10201601046QA (en) 2016-03-30
MX2013009420A (es) 2013-12-16
EP2675480B1 (en) 2018-12-26
MY169448A (en) 2019-04-11
MX346635B (es) 2017-03-27
IL227964A (en) 2017-09-28
CN103702686B (zh) 2016-11-23
CN107050468A (zh) 2017-08-18
EP2675479B1 (en) 2016-01-13
WO2012112708A1 (en) 2012-08-23
KR20140010076A (ko) 2014-01-23
CA2825919C (en) 2018-05-01
US10179818B2 (en) 2019-01-15
US20150099874A1 (en) 2015-04-09
HK1186686A1 (zh) 2014-03-21
US20190263924A1 (en) 2019-08-29
CA3034596A1 (en) 2012-09-27
JP2014506892A (ja) 2014-03-20
ME02381B (me) 2016-06-20
CY1121532T1 (el) 2020-05-29
JP6049642B2 (ja) 2016-12-21
BR112013020540B1 (pt) 2020-12-29
EP2675481A1 (en) 2013-12-25
CY1117340T1 (el) 2017-04-26
EP3053600B1 (en) 2020-01-29
KR20190051081A (ko) 2019-05-14
HRP20160164T1 (hr) 2016-03-11
RU2013141829A (ru) 2015-03-27
EP2675480A1 (en) 2013-12-25
US20180037659A1 (en) 2018-02-08
KR20200141534A (ko) 2020-12-18
IL227963A0 (en) 2013-09-30
CN107335061B (zh) 2021-09-07
JP2018027966A (ja) 2018-02-22
JP5826863B2 (ja) 2015-12-02
TW201309674A (zh) 2013-03-01
CN113896731A (zh) 2022-01-07
UA120696C2 (uk) 2020-01-27
KR20190089048A (ko) 2019-07-29
IL254128A0 (en) 2017-10-31
US20120244171A1 (en) 2012-09-27
US20120238731A1 (en) 2012-09-20
US20180002440A1 (en) 2018-01-04
AU2012231640B2 (en) 2015-07-09
RU2621035C2 (ru) 2017-05-31
US20160324980A1 (en) 2016-11-10
IL279304B (en) 2022-07-01
SG10202007640VA (en) 2020-09-29
IL279304A (en) 2021-01-31
JP2019142928A (ja) 2019-08-29
CA2825919A1 (en) 2012-08-23
LT2675480T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
SMT201600099B (it) Derivati citotossici di benzodiazepine
SMT201500270B (it) Derivati di pirrolotriazinone come inibitori di pi3k
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201600020B (it) Derivati di benzilammina come inibitori di callicreina plasmatica
ME03469B (me) DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU
SMT201600108B (it) Derivato di pirazochinolina come inibitori di pde9
EP2720699A4 (en) ADMINISTRATION OF BENZODIAZEPINE
HRP20170279T1 (hr) Derivati benzimidazola kao inhibitori pi3-kinaze
SMT201900679T1 (it) Derivati deuterati di ivacaftor
CO6920296A2 (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CO6870035A2 (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
SMT201600205B (it) DERIVATI BENZOTIOFENICI SOSTITUITI CON PIPERAZINA COME AGENTI ANTlPSICOTICI
HRP20170196T1 (hr) Derivati dušikovih iperita
ME03782B (me) Derivati pirimidina za tretman virusnih infekcija
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
SMT201600153B (it) Derivato di azolo
CO6930367A2 (es) Composiciones farmaceúticas
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2691100A4 (en) INTRANASAL PHARMACEUTICAL BENZODIAZEPINE COMPOSITIONS
CO6801764A2 (es) Derivados de pirazol
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
HUE040370T2 (hu) Gyógyszerkészítmények
SMT201300067B (it) Applicazioni terapeutiche di derivati di chinazolindione
ITMI20112329A1 (it) Nuovi derivati spiro amminici